AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10321421 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro Mix50 (50% insulin lispro/50% NPL)
Number of subjects: 100
Study 10321421 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro Mix25 (25% insulin lispro/75% NPL)
Number of subjects: 100
Study 10321421 — intervention group
Group type: COMPARATOR
Intervention: Human insulin 50/50 (50% regular insulin/50% NPH insulin)
Number of subjects: 100
Study 10321421 — intervention group
Group type: COMPARATOR
Intervention: Human insulin 30/70 (30% regular insulin/70% NPH)
Number of subjects: 100
Study 10321421 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mixtures
Number of subjects: 100
Study 8921782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cholesterol (milligrams per 1000 kilocalories)
Number of subjects: 11342
Study 8921782 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (percent of kilocalories)
Number of subjects: 11342
Study 8921782 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch (percent of kilocalories)
Number of subjects: 11342
Study 8921782 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein
Number of subjects: 11342
Study 8921782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of dietary polyunsaturated to saturated fatty acids
Number of subjects: 11342
Study 8921782 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass, dietary sodium and ratio of sodium to potassium, and alcohol intake
Number of subjects: 11342
Study 8921782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of potassium and caffeine
Number of subjects: 11342
Study 1872515 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate as sustained-release tablets of 22 mg Zn++ (Zinklet), administered three times daily for 8 weeks
Number of subjects: 48
Study 1872515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6820504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg three times per day
Number of subjects: 9
Study 31444815 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-MY20 Disease Symptoms (DS)
Number of subjects: 0
Study 31444815 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-MY20 Side Effects of Treatment (SE)
Number of subjects: 0
Study 31444815 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-MY20 Body Image (BI)
Number of subjects: 0
Study 31444815 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-MY20 Future Perspective (FP)
Number of subjects: 0
Study 27696727 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol treatment for axial SpA
Number of subjects: 47
Study 27696727 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol treatment for PsA
Number of subjects: 47
Study 26139231 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 30
Study 23788270 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with irinotecan or temozolomide after 2 chemotherapy cycles (8 weeks)
Number of subjects: 123
Study 23788270 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with irinotecan or temozolomide after 4 chemotherapy cycles (16 weeks)
Number of subjects: 123
Study 21782519 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E) 0, 1, 2 month schedule
Number of subjects: 511
Study 21782519 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E) 0, 1, 7 month schedule
Number of subjects: 511
Study 21782519 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 511
Study 19674936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium clodronate (2080 mg, four tablets per day) for up to 3 years (metastatic disease) or 5 years (non-metastatic)
Number of subjects: 819
Study 19674936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 819
Study 17514693 — intervention group
Group type: EXPERIMENTAL
Intervention: Early open surgical repair
Number of subjects: 1090
Study 17514693 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 1090
Study 17514693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1090
Study 15352908 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 71
Study 15352908 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 71
Study 12161007 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) administered intravenously at a dose of 2.5 IU
Number of subjects: 0
Study 12161007 — intervention group
Group type: COMPARATOR
Intervention: Vehicle administration (control)
Number of subjects: 0
Study 9617509 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg daily
Number of subjects: 45
Study 9617509 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 10 mg daily
Number of subjects: 45
Study 9617509 — intervention group
Group type: COMPARATOR
Intervention: Lithium 800 to 1200 mg daily
Number of subjects: 45
Study 7654645 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineoplasty
Number of subjects: 21
Study 7654645 — intervention group
Group type: COMPARATOR
Intervention: Vestibuloplasty
Number of subjects: 21
Study 1812444 — intervention group
Group type: EXPERIMENTAL
Intervention: Test packs (nylon sleeves)
Number of subjects: 7200
Study 1812444 — intervention group
Group type: COMPARATOR
Intervention: Control packs (nylon sleeves)
Number of subjects: 7200
Study 1812444 — intervention group
Group type: EXPERIMENTAL
Intervention: Test packs (paper envelopes)
Number of subjects: 7200
Study 1812444 — intervention group
Group type: COMPARATOR
Intervention: Control packs (paper envelopes)
Number of subjects: 7200
Study 1812444 — intervention group
Group type: EXPERIMENTAL
Intervention: Test packs (peel pouches)
Number of subjects: 7200
Study 1812444 — intervention group
Group type: COMPARATOR
Intervention: Control packs (peel pouches)
Number of subjects: 7200
Study 7018166 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2-tablets (0.5-1.5 mg/hr)
Number of subjects: 201
Study 7018166 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (7.5-45 mIU/min)
Number of subjects: 201
Study 30167831 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial hydronephrosis (group A)
Number of subjects: 300
Study 30167831 — intervention group
Group type: COMPARATOR
Intervention: No hydronephrosis (group B)
Number of subjects: 300
Study 28120350 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhealba® Oat Extract-based emollient applied once or twice daily during a 2-week treatment phase
Number of subjects: 30
Study 28120350 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhealba® Oat Extract-based emollient
Number of subjects: 30
Study 26468934 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 376
Study 26468934 — intervention group
Group type: COMPARATOR
Intervention: PGE2 (dinoprostone insert)
Number of subjects: 376
Study 24499078 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS), Group A: n = 35
Number of subjects: 72
Study 24499078 — intervention group
Group type: COMPARATOR
Intervention: PAD drugs (cilostazol or sarpogrelate), Group B: n = 37
Number of subjects: 72
Study 21951464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant overdentures (IODs)
Number of subjects: 255
Study 21951464 — intervention group
Group type: COMPARATOR
Intervention: Complete dentures (CDs)
Number of subjects: 255
Study 18977113 — intervention group
Group type: EXPERIMENTAL
Intervention: Information + self‐regulation intervention
Number of subjects: 256
Study 18977113 — intervention group
Group type: COMPARATOR
Intervention: Information intervention
Number of subjects: 256
Study 17516958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (150 g tablet, containing 50 mg of elemental iron) daily throughout pregnancy (n = 370)
Number of subjects: 727
Study 17516958 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily throughout pregnancy (n = 357)
Number of subjects: 727
Study 15702062 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.0134% in 10 ml intrathecal volume for spontaneous labor
Number of subjects: 75
Study 15702062 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.0195% in 10 ml intrathecal volume for induced labor
Number of subjects: 75
Study 15702062 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (general outcome)
Number of subjects: 75
Study 11270910 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (200 mg/day)
Number of subjects: 100
Study 11270910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9673725 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 46
Study 9673725 — intervention group
Group type: COMPARATOR
Intervention: No anaesthesia
Number of subjects: 46
Study 8011502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (6 g/day of concentrated n-3 fatty acids)
Number of subjects: 145
Study 8011502 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (isoenergetic amount)
Number of subjects: 145
Study 2685677 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm Labor Detection Clinic Program
Number of subjects: 943
Study 2685677 — intervention group
Group type: COMPARATOR
Intervention: High-risk controls
Number of subjects: 943
Study 2685677 — intervention group
Group type: COMPARATOR
Intervention: Low-risk controls
Number of subjects: 943
Study 322520 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 322520 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 0
Study 322520 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydroxychloroquine and aspirin
Number of subjects: 0
Study 322520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31718229 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure (n=17, two training sessions followed by self-practice for 6 weeks)
Number of subjects: 35
Study 31718229 — intervention group
Group type: COMPARATOR
Intervention: Knee health education (n=18, two health education sessions about KOA management followed by self-care for 6 weeks)
Number of subjects: 35
Study 31718229 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure
Number of subjects: 35
Study 31718229 — intervention group
Group type: COMPARATOR
Intervention: Knee health education
Number of subjects: 35
Study 31775798 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition B - Reduced slots for less-healthy drinks
Number of subjects: 10
Study 31775798 — intervention group
Group type: COMPARATOR
Intervention: Condition A - Standardised levels of healthier products
Number of subjects: 10
Study 31775798 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition C - Increased slots for healthier products
Number of subjects: 10
Study 31775798 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition D - Reduced slots for healthier snacks
Number of subjects: 10
Study 31775798 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition E - Increased slots for less-healthy products
Number of subjects: 10
Study 28760194 — intervention group
Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty (UPPP)
Number of subjects: 40
Study 28760194 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Radiofrequency Tissue Ablation (MRFTA)
Number of subjects: 40
Study 28760194 — intervention group
Group type: COMPARATOR
Intervention: MRFTA
Number of subjects: 40
Study 28760194 — intervention group
Group type: COMPARATOR
Intervention: UPPP
Number of subjects: 40
Study 25858205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics program
Number of subjects: 2
Study 25858205 — intervention group
Group type: COMPARATOR
Intervention: Control hospital
Number of subjects: 2
Study 23868428 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic partial arytenoidectomy
Number of subjects: 20
Study 23868428 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic total arytenoidectomy
Number of subjects: 20
Study 23868428 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic total and partial arytenoidectomy
Number of subjects: 20
Study 19604587 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy (including fibrinolysis and primary PCI)
Number of subjects: 5867
Study 19604587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 5867
Study 19604587 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 5867
Study 19604587 — intervention group
Group type: COMPARATOR
Intervention: No early reperfusion therapy
Number of subjects: 5867
Study 20196389 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surfactant administration (2 hours after the first dose)
Number of subjects: 40
Study 20196389 — intervention group
Group type: COMPARATOR
Intervention: Late surfactant administration (6 hours after the first dose)
Number of subjects: 40
Study 16769945 — intervention group
Group type: EXPERIMENTAL
Intervention: Friedreich Ataxia Rating Scale (FARS)
Number of subjects: 155
Study 16769945 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance measures (9‐hole peg test, timed 25‐foot walk, PATA test, low‐contrast letter acuity)
Number of subjects: 155
Study 16769945 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite measures created using cohort means and standard deviations
Number of subjects: 155
Study 15050490 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial velocity profile (MVP) using color‐coded tissue Doppler imaging (TDI) in patients with cardiac amyloidosis
Number of subjects: 80
Study 15050490 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinically normal controls)
Number of subjects: 80
Study 11734414 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb starting position visible during prism exposure
Number of subjects: 56
Study 11734414 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback available early or late in target pointing movements
Number of subjects: 56
Study 11734414 — intervention group
Group type: COMPARATOR
Intervention: Limb starting position not visible during prism exposure
Number of subjects: 56
Study 11734414 — intervention group
Group type: COMPARATOR
Intervention: Visual feedback not available
Number of subjects: 56
Study 9408721 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of randomized trials
Number of subjects: 0
Study 9408721 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of small trials
Number of subjects: 0
Study 9408721 — intervention group
Group type: EXPERIMENTAL
Intervention: Large trials
Number of subjects: 0
Study 8387085 — intervention group
Group type: EXPERIMENTAL
Intervention: lacto-ovovegetarian diet
Number of subjects: 21
Study 8387085 — intervention group
Group type: COMPARATOR
Intervention: omnivorous diet
Number of subjects: 21
Study 3120571 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-ovovegetarian diet (L)
Number of subjects: 12
Study 3120571 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet (V)
Number of subjects: 12
Study 3120571 — intervention group
Group type: COMPARATOR
Intervention: Mixed diet (M)
Number of subjects: 12
Study 30547749 — intervention group
Group type: COMPARATOR
Intervention: Repellent (N,N‐diethyl‐benzamide - 12% w/w, cream) distributed by Village Health Volunteers (VHVs) during the malaria transmission season.
Number of subjects: 0
Study 26485693 — intervention group
Group type: EXPERIMENTAL
Intervention: v-CPR
Number of subjects: 180
Study 26485693 — intervention group
Group type: COMPARATOR
Intervention: t-CPR
Number of subjects: 180
Study 25042931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 16
Study 25042931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22838228 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 30
Study 22838228 — intervention group
Group type: COMPARATOR
Intervention: Calcium Hydroxide
Number of subjects: 30
Study 20510211 — intervention group
Group type: EXPERIMENTAL
Intervention: High bolus dose tirofiban
Number of subjects: 1398
Study 20510211 — intervention group
Group type: COMPARATOR
Intervention: No tirofiban (phase 1) or placebo (phase 2)
Number of subjects: 1398
Study 19835025 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 71
Study 19835025 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 71
Study 17064548 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group
Number of subjects: 110
Study 17064548 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 12812864 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day methylprednisolone given IV for 5 days, then PO taper down
Number of subjects: 9
Study 12812864 — intervention group
Group type: COMPARATOR
Intervention: Healthy female controls
Number of subjects: 9
Study 10754621 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiluted propofol infusion at rates of 10, 15, 20, 30, 40, 60, 100, 200, and 300 mg/kg‐1/h‐1
Number of subjects: 250
Study 10754621 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted propofol (0.5 mg/ml) infusion at rates of 10, 15, 30, 60, 100, 200, and 300 mg/kg‐1/h‐1
Number of subjects: 250
Study 10754621 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid infusion at the same rates as group C
Number of subjects: 250
Study 8796792 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg/2 ml PGE2 gel
Number of subjects: 229
Study 8796792 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/2 ml PGE2 gel
Number of subjects: 229
Study 8796792 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/2 ml PGE2 gel
Number of subjects: 229
Study 8796792 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 229
Study 1639464 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml/kg ethanol (vodka)
Number of subjects: 16
Study 1639464 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic beverage
Number of subjects: 16
Study 6539613 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric juice-resistant formulation of cyclophosphamide (CP)
Number of subjects: 12
Study 6539613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid release formulation 1 of cyclophosphamide (CP)
Number of subjects: 12
Study 6539613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid release formulation 2 of cyclophosphamide (CP)
Number of subjects: 12
Study 6539613 — intervention group
Group type: COMPARATOR
Intervention: Intravenous application of cyclophosphamide (CP)
Number of subjects: 12
Study 30653342 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT-2 (10 × 60 s cycling, ∼83% peak power output, 2 times per week for 8 weeks)
Number of subjects: 35
Study 30653342 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT-3 (10 × 60 s cycling, ∼83% peak power output, 3 times per week for 8 weeks)
Number of subjects: 35
Study 30653342 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 35
Study 30838824 — intervention group
Group type: EXPERIMENTAL
Intervention: Noble metal coated CVC
Number of subjects: 45
Study 30838824 — intervention group
Group type: COMPARATOR
Intervention: Uncoated CVC
Number of subjects: 45
Study 26335243 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative clinical diagnosis based on computed tomography or magnetic resonance imaging
Number of subjects: 166
Study 26335243 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative clinical diagnosis
Number of subjects: 166
Study 24971786 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal gonadotropins
Number of subjects: 78
Study 24971786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multivitamin)
Number of subjects: 78
Study 22768793 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR intervention (IVR screening plus automated questions to identify barriers and offer transfer to QL)
Number of subjects: 521
Study 22768793 — intervention group
Group type: COMPARATOR
Intervention: Control group (IVR screening for current smoking without intervention)
Number of subjects: 521
Study 22768793 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR intervention
Number of subjects: 521
Study 21058209 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise program with ankle weights
Number of subjects: 21
Study 21058209 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study 18339108 — intervention group
Group type: EXPERIMENTAL
Intervention: MET/CBT coping skills training
Number of subjects: 240
Study 18339108 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (ContM)
Number of subjects: 240
Study 18339108 — intervention group
Group type: EXPERIMENTAL
Intervention: MET/CBT + ContM
Number of subjects: 240
Study 18339108 — intervention group
Group type: COMPARATOR
Intervention: Case management control condition
Number of subjects: 240
Study 15765254 — intervention group
Group type: EXPERIMENTAL
Intervention: Climodien (estradiol valerate 2 mg and dienogest 3 mg)
Number of subjects: 55
Study 15765254 — intervention group
Group type: COMPARATOR
Intervention: Estradiol valerate (EV) 2 mg alone
Number of subjects: 55
Study 15765254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 12081158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg daily
Number of subjects: 20
Study 12081158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10572334 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram plus clomipramine (n = 9)
Number of subjects: 16
Study 10572334 — intervention group
Group type: COMPARATOR
Intervention: Citalopram alone (n = 7)
Number of subjects: 16
Study 10572334 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (n = 6) for patients who did not tolerate fluoxetine or clomipramine alone
Number of subjects: 16
Study 7603935 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (booklet with adjunct questions)
Number of subjects: 90
Study 7603935 — intervention group
Group type: COMPARATOR
Intervention: Treatment control group (booklet without adjunct questions)
Number of subjects: 90
Study 7603935 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment control group
Number of subjects: 90
Study 2196621 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 18
Study 2196621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18